MyFinsight
Home
Blog
About
Contact
Download
Download image
Preferred stock offering
$5,455,000
Shares issued for cash
$4,558,455
Shares issued for sepa
$2,958,848
Proceeds from notes
payable
$990,000
Pre-funded warrants
exercise
$900
Net cash provided by
financing activities
$13,744,453
Canceled cashflow
$218,750
Net increase
(decrease) in cash
$5,141,417
Canceled cashflow
$8,603,036
Repayment of notes payable
-$218,750
Shares issued for
non-employee services
$3,829,220
Stock based
compensation
$1,215,692
Depreciation and
amortization
$1,181,212
Warrants issued for
services
$824,295
Amortization of debt discount
$545,635
Unrealized loss on
investments
-$163,500
Right of use asset
amortization
$41,385
Net cash used in
operating activities
-$8,603,036
Canceled cashflow
$7,800,939
Net loss
-$12,277,192
Non-cash revenue
$1,333,045
Change in fair value of
derivative liability
$906,430
Prepaid assets
$473,497
Accrued expenses
-$440,889
Accounts payable
-$381,012
Change in fair value of
derivative liability...
-$191,625
(gain) loss on
extinguishment of debt
$159,035
Other current
liabilities
-$115,000
Unrealized gain on
marketable securities
$76,596
Right of use liability
-$42,306
Interest receivable
$7,348
Back
Back
Cash Flow
source: myfinsight.com
Coeptis Therapeutics Holdings, Inc. (COEPW)
Coeptis Therapeutics Holdings, Inc. (COEPW)